Cpi 613
Cpi 613 is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 3 | 1 | — | — | 5 |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 2 | 2 | — | — | — | 3 | |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 2 | — | — | — | 2 | |
| Lymphoma | D008223 | C85.9 | 1 | 1 | — | — | — | 2 | |
| Clear cell sarcoma | D018227 | 1 | 1 | — | — | — | 1 | ||
| Pancreatic ductal carcinoma | D021441 | — | 1 | — | — | — | 1 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | — | 1 | — | — | — | 1 | |
| T-cell lymphoma | D016399 | — | 1 | — | — | — | 1 | ||
| Biliary tract neoplasms | D001661 | C24.9 | 1 | 1 | — | — | — | 1 | |
| Leukemia | D007938 | C95 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CPI 613 |
| INN | devimistat |
| Description | Devimistat (INN; development code CPI-613) is an experimental anti-mitochondrial drug being developed by Cornerstone Pharmaceuticals. It is being studied for the treatment of patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML).
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CCCCC(CCSCc1ccccc1)SCc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 95809-78-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3186849 |
| ChEBI ID | — |
| PubChem CID | 24770514 |
| DrugBank | DB12109 |
| UNII ID | E76113IR49 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 363 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more